The postdoctoral researcher will work on two distinct pharmacoepidemiology-focused studies, each led by a faculty member in the Division of Epidemiology.
Dr. Charles Leonard, a clinical pharmacist and pharmacoepidemiologist, is PI of a study entitled “Drug Interactions Involving Psychoactive Drugs”. This study will: i) conduct high-throughput automated screening of longitudinal healthcare data to identify potential drug interaction pairs and triads leading to unintentional traumatic injury, including hip fractures and motor vehicle crashes; ii) convene a multidisciplinary Expert Panel to review screening results, prioritize signals for further investigation, and prespecify hypotheses buttressed by putative mechanisms; and iii) conduct a series of rigorous pharmacoepidemiologic studies to inform causal inferences and thereby generate clinically actionable evidence on drug interactions to prevent instances of unintentional traumatic injury.
Dr. James Lewis, a gastroenterologist and pharmacoepidemiologist, is PI of a study entitled “Defining the Incidence, Prevalence, and Treatment Patterns of Inflammatory Bowel Disease in the United States”. This study will: i) build a registry of patients with incident diagnosis of Crohn’s Disease and ulcerative colitis; ii) estimate the incidence and prevalence of Crohn’s Disease and ulcerative colitis at a national level using representative data from four large claims datasets that encompasses populations from all segments of the socioeconomic and geographic distribution of the United States; and iii) determine whether race and inflammatory bowel disease practice volume are associated with patterns of care and key outcomes including use of biologics, steroids, narcotics, hospitalization and surgery at a national level and within high volume inflammatory bowel disease centers.
ABOUT THE UNIVERSITY OF PENNSYLVANIA:
The University of Pennsylvania’s Perelman School of Medicine is the oldest medical school in the US. We are rich in tradition and heritage and at the same time consistently at the forefront of new developments and innovations in medical education and research. Since the medical school’s founding in 1765, we have been a strong presence in the community and prided ourselves on educating the leaders of tomorrow in patient care, biomedical research, and medical education. The Perelman School of Medicine consistently ranks among the top five in US News and World Report’s rankings of research-oriented medical schools. Our mission is to advance knowledge and improve health through research, patient care, and the education of trainees in an inclusive culture that embraces diversity, fosters innovation, stimulates critical thinking, supports lifelong learning, and sustains our legacy of excellence. The Department of Biostatistics, Epidemiology and Informatics is home to more than 100 faculty and the graduate education programs in these three core disciplines. Most faculty are also a member of the Center for Clinical Epidemiology and Biostatistics, an interdisciplinary and interdepartmental program that links clinical epidemiology and biostatistics within the Perelman School of Medicine, the University of Pennsylvania Health System, and the Penn community.
Start Date: 02/01/2019 (anticipated, but flexible)
End Date: As late as 08/31/2023, although appointed in 1-year terms at the discretion of the PIs.
A PhD, ScD, or related doctoral degree in epidemiology, preferably with a concentration in pharmacoepidemiology
Additional Salary Information: Stipend set by the University of Pennsylvania’s Office of the Vice Provost for Research, https://almanac.upenn.edu/articles/of-record-fy2019-postdoc-stipends
Internal Number: 001
About University of Pennsylvania | Perelman School of Medicine
Penn's Center for Pharmacoepidemiology Research and Training (CPeRT), based in the Center for Clinical Epidemiology and Biostatistics (CCEB) and led by Dr. Sean Hennessy, was established in 2012 to improve public health and advance science by conducting leading-edge, interdisciplinary research in pharmacoepidemiology, and to train the next generation of research leaders in pharmacoepidemiology. Despite CPeRT’s recent establishment, Penn investigators have been leaders in pharmacoepidemiology since the field’s inception in the early 1980s.
CPeRT includes nearly 100 investigators (Penn faculty engaged in pharmacoepidemiology research), adjunct investigators (whose primary affiliation is outside of Penn), and Investigators-in-Training. CPeRT helps to lead Penn’s Master of Science in Clinical Epidemiology- and PhD-granting pharmacoepidemiology training programs, hosts a weekly Pharmacoepidemiology Rounds series, hosts a monthly Research-in-Progress series, hosts visiting pharmacoepidemiology methodologists, maintains phamacoepidemiologic research databases, and funds pilot projects. CPeRT members are leaders in the development, evaluation and application of new methods to study the ...health effects of medications in populations. CPeRT is an academic partner of the FDA-funded Sentinel Initiative and houses the American editorial office of the journal Pharmacoepidemiology and Drug Safety. CPeRT members also edit the books Pharmacoepidemiology and Textbook of Pharmacoepidemiology.